Orris

Pcos to pmos

Asking for Preferences

Newer updates in pcos and change in its name

Reading File
Finding Sources
Searching PubMed

polycystic ovary syndrome rename PMOS 2023 2024

Searching the Web

PCOS renamed PMOS polycystic ovary syndrome new name 2023 2024 guidelines update

Finding Sources
Searching PubMed

polycystic ovary syndrome guidelines 2023 update management

Reading Web Page

https://www.ajmc.com/view/pcos-renamed-pmos-in-landmark-shif…

Excellent - I now have comprehensive information. Let me compile the full answer.

PCOS Renamed PMOS: The Landmark 2026 Update

The Name Change

On May 12, 2026, a global consensus published in The Lancet (Teede HJ et al.) officially renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This followed an extensive international process involving the International PCOS Network and over 14,000 survey responses from patients and healthcare professionals across multiple regions.
Reference: Teede HJ et al., The Lancet, May 2026

Why Was the Name Changed?

The old name "Polycystic Ovary Syndrome" was considered inaccurate and misleading for several key reasons:
Problem with "PCOS"Explanation
"Cysts" is a misnomerThe ovarian morphology seen in PCOS is follicular (multiple small follicles), not true cysts. Not all patients have polycystic ovaries on ultrasound.
Ovary-centric framingThe condition is fundamentally a multi-system endocrine and metabolic disorder, not just an ovarian problem.
Missed diagnosesPatients with irregular cycles, hyperandrogenism, and insulin resistance but no visible ovarian cysts were often not diagnosed.
Metabolic risks underplayedThe name failed to signal the significant risks of insulin resistance, type 2 diabetes, dyslipidemia, cardiovascular disease, and hypertension.
StigmaFocus on "cysts" and "ovaries" caused reproductive stigma and undervalued the broader hormonal picture.

Breaking Down the New Name: PMOS

  • Poly-endocrine - Acknowledges involvement of multiple hormonal systems: insulin, androgens, LH/FSH dysregulation, neuroendocrine hormones. Infertility is driven by multiple interacting hormonal disturbances, not just an isolated ovarian issue.
  • Metabolic - Highlights the central role of insulin resistance and metabolic dysfunction (present in the majority of patients, including lean women).
  • Ovarian - Retained to reflect the reproductive and ovulatory effects that remain a key feature.
  • Syndrome - Maintained as it still represents a constellation of features.

2023 International Evidence-Based Guideline Updates

Even before the renaming, the 2023 International Evidence-Based PCOS Guideline (Teede HJ et al., published in Fertility & Sterility, JCEM, and European Journal of Endocrinology - PMID: 37589624) brought major updates:

Diagnostic Updates

  • Rotterdam criteria retained (2 of 3: oligo/anovulation, clinical/biochemical hyperandrogenism, polycystic ovarian morphology - PCOM)
  • Anti-Mullerian Hormone (AMH) can now replace ultrasound for PCOM assessment in adults (updated AMH thresholds provided based on assay type)
  • Ultrasound follicle count threshold updated to ≥20 follicles per ovary (raised from ≥12) based on modern high-resolution probes
  • In adolescents: diagnosis requires both irregular cycles AND hyperandrogenism (PCOM alone insufficient due to normal physiology)

Cardiovascular Risk (2024 Systematic Review - PMID: 39119982)

  • PMOS patients have significantly elevated clinical cardiovascular disease risk - this was formally quantified
  • Routine cardiometabolic screening (lipids, glucose, BP) recommended for all patients

Metabolic Management

  • Metformin + combined oral contraceptive pills shown beneficial for metabolic and reproductive outcomes (PMID: 37554096)
  • Inositol (myo-inositol) - now formally reviewed with evidence supporting use for metabolic and reproductive outcomes (PMID: 38163998)
  • Lifestyle modification (diet + exercise) remains first-line for all phenotypes

Mental Health

  • Anxiety, depression, and reduced quality of life formally recognized as core features requiring screening and management

Lifespan Approach

  • 2023 guideline emphasizes care must address reproductive, metabolic, cardiovascular, dermatologic, sleep, and psychological features across the lifespan, not just fertility

Summary: Key Takeaway

The rename from PCOS to PMOS is not merely cosmetic. It reflects a fundamental reconceptualization of the condition as a complex polyendocrine-metabolic disorder affecting ~170 million women globally. The goal is to:
  1. Improve diagnostic accuracy (especially in non-obese, non-cystic presentations)
  2. Direct treatment toward underlying metabolic drivers (insulin resistance)
  3. Reduce stigma
  4. Strengthen research consistency across the world
The Society for Endocrinology announced the change on May 12, 2026, and institutions like Medscape have already updated their clinical guidelines pages to reflect the new terminology.
This is a shared conversation. Sign in to Orris to start your own chat.